You mean the 2021 hybrid ECA put together by AI?; ). You do realize that this was done AFTER agreement by regulators to NWBO’s SAP?; ). They took their Phase 2 data and used AI to develop a hybrid model that reduces the number of control patients by 2/3. NWBO had a mandated crossover that eliminated the possibility of a usable control arm due to patients receiving a potentially active treatment at crossover.., which it was. So guess what? Medicenna does not mention external controls but rather data obtained from their own patients from their Phase 2 to match with a larger data base. No issues obtaining that data huh?; ). Best wishes.
Market Data 
Markets 
AI
